Formulation strategies to modulate the topical delivery of anti-inflammatory compounds

Journal of Cosmetic Science

Volumn 64, Issue 5, 2013, Pages 341-353

  Puglia, Carmelo ^a   Rizza, Luisa ^a   Offerta, Alessia ^a   Gasparri, Franco ^b   Giannini, Valentina ^b   Bonina, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Rotta Research Laboratorium   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DRUG CARRIER; DRUG DERIVATIVE; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; NANOPARTICLE; PHOSPHATIDYLCHOLINE; STEARYL GLYCYRRHETINATE; EMULSION; GEL;

ADULT; ARTICLE; DRUG EFFECT; EMULSION; ERYTHEMA; FEMALE; GEL; HUMAN; HYDROGENATION; MALE; METABOLISM; PARTICLE SIZE; PATHOLOGY; PERMEABILITY; SKIN; SKIN ABSORPTION; TOPICAL DRUG ADMINISTRATION; ULTRAVIOLET RADIATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; DRUG CARRIERS; EMULSIONS; ERYTHEMA; FEMALE; GELS; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; HUMANS; HYDROGENATION; LECITHINS; MALE; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; SKIN; SKIN ABSORPTION; ULTRAVIOLET RAYS;

EID: 84891658370     PISSN: 15257886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. M. N. Asl and H. Hosseinzadeh, Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds, Phytother. Res., 22, 709–724 (2008).
2. G. L. Capella and A. F. Finzi, Complementary therapy for psoriasis, Dermatol. Ther., 16, 164–174 (2003).
3. S. Yano, Experiment on the essentials of corticoid activity of glycyrrhizin,. J. Jpn. Assoc. Endoc., 34, 745–751 (1958).
4. M. Kerube, Study on mechanism of anti-inflammatory action of glycyrrhetinic acid, J. Keio. Med. Soc., 47, 331–344 (1970).
5. J. Hadgraft, “Formulation of Anti-Inflammatory Agents,” in Nonsteroidal Anti-Inflammatory Drugs, Pharmacology and Skin, C. Hensby and N. J. Lowe. Eds. (Karger, Basel, 1989), Vol. 2, pp. 21–43.
6. A. C. Williams and B. W. Barry, Penetration enhancers, Adv. Drug Deliv. Rev., 56, 603–618 (2004).
7. A. G. Doukas and N. Kollias, Transdermal drug delivery with a pressure wave, Adv. Drug Deliv. Rev., 56, 559–579 (2004).
8. C. Puglia, R. Filosa, A. Peduto, P. de Caprariis, L. Rizza, F. Bonina, and P. Blasi, Evaluation of alternative strategies to optimize ketorolac transdermal delivery, AAPS Pharm. Sci. Tech., 7, 64 (2006).
9. J. Hadgraft, Skin: The final frontier, Int. J. Pharm., 224, 1–18 (2001).
10. R. H. Muller, M. Radtke, and S. A. Wissing, Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations, Adv. Drug Deliv. Rev., 54, S131–S155 (2002).
11. C. Puglia and F. Bonina, Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals, Expert Opin. Drug Deliv., 9, 429–441 (2012).
12. M. Ricci, C. Puglia, F. Bonina, C. Di Giovanni, S. Giovagnoli, and C. Rossi, Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC): In vitro and in vivo studies, J. Pharm. Sci., 94, 1149–1159 (2005).
13. C. Puglia, P. Blasi, L. Rizza, A. Schoubben, M. Ricci, F. Bonina, and C. Rossi, Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation, Int. J. Pharm., 357, 295–304 (2008).
14. K. Mitri, R. Shegokar, S. Gohla, C. Anselmi, and R. H. Müller, Lipid nanocarriers for dermal delivery of lutein: Preparation, characterization, stability, and performance, Int. J. Pharm., 414, 267–275 (2011).
15. C. Puglia, G. Frasca, T. Musumeci, L. Rizza, G. Puglisi, F. Bonina, and S. Chiechio, Curcumin loaded NLC induces histone hypoacetylation in the CNS after intraperitoneal administration in mice, Eur. J. Pharm. Biopharm., 81, 288–293 (2012).
16. A. M. Kligman and E. Christophers, Preparation of isolated sheets of human stratum corneum, Arch. Dermatol., 88, 702–705 (1963).
17. J. Swarbrick, G. Lee, and J. Brom, Drug permeation through human skin. I: Effects of storage conditions of skin, J. Invest. Dermatol., 78, 63–66 (1982).
18. R. L. Bronaugh, R. F. Stewart, and M. Simon, Methods for in vitro percutaneous absorption studies VII: Use of excised human skin, J. Pharm. Sci., 75, 1094–1097 (1986).
19. E. Touitou and B. Fabin, Altered skin permeation of a highly lipophilic molecule: Tetrahydrocannabi-nol, Int. J. Pharm., 43, 17–22 (1988).
20. M. Siewert, J. Dressman, C. K. Brown, and V. P. Shah, FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms, AAPS Pharm. Sci. Tech., 4, E7 (2003).
21. E. Esposito, R. Cortesi, M. Drechsler, L. Paccamiccio, P. Mariani, C. Contado, E. Stellin, E. Menegatti, F. Bonina, and C. Puglia, Cubosome dispersions as delivery systems for percutaneous administration of indomethacin, Pharm. Res., 22, 2163–2173 (2005).
22. J.B. Dawson, D. J. Barker, D. J. Ellis, E. Grassam, J. A. Cotterill, G. W. Fisher, and J. W. Feather, A theoretical and experimental study of light absorption and scattering by in vivo skin, Phys. Med. Biol., 25, 695–709 (1980).
23. R. J. Scheuplein and I. H. Blank, Mechanism of percutaneous absorption. IV. Penetration of nonelectro-lytes (alcohols) from aqueous solution and from pure liquid, J. Invest. Dermatol., 60, 286–296 (1973).